European Society of Gene & Cell Therapy 2026 Congress

Aurealis Therapeutics attended the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, held in collaboration with the German Society of Gene Therapy (DG-GT) from 27 to 30 October 2026 at the Congress Center Hamburg. CTO Hanna Lesch and COO Laurent Décory represented the company.

The congress brought together researchers, clinicians and industry professionals to share the latest research and advances in gene and cell therapy. Hanna also attended as Chair of the ESGCT Manufacturing Committee.

Share the event:

other recent events:

European Wound Management Association 2026 Conference

Aurealis Therapeutics shared the results of its DIAMEND Phase 2 clinical trial of AUP-16 for non-healing Diabetic Foot Ulcers (DFUs) at the European Wound Management Association (EWMA) 2026 Conference, taking place from 6–8 May in Bremen, Germany. The results were presented by Professor Alberto Piaggesi, Global Coordinating Investigator of the study on Thursday 7 May, 2026. In addition, Aurealis’ CEO

Read More »

Week of Strategic Meetings in China 2025

During the week of 20–25 October 2025, Aurealis Therapeutics’ CEO Juha Yrjänheikki and COO Laurent Décory traveled to Beijing, Shanghai and Hong Kong for a series of high-level meetings with key stakeholders, investors, and potential partners. The visit aimed to strengthen strategic relationships that support the development and commercialisation of Aurealis’ multi-target cell and gene therapy candidates, AUP-16 for chronic

Read More »